Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Basal Cell 25Pancreatic Neoplasms 8Neoplasms 8Prostatic Neoplasms 5Multiple Myeloma 5Medulloblastoma 5Breast Neoplasms 5Skin Neoplasms 4Ovarian Neoplasms 4Basal Cell Nevus Syndrome 4Stomach Neoplasms 3Hematologic Neoplasms 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Sarcoma 2Neoplasms, Basal Cell 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lymphoma 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Glioblastoma 2Chondrosarcoma 2Carcinoma 2Brain Neoplasms 2Adenocarcinoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1

Interventions

atezolizumab 1HhAntag691 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Platinum-Resistant Fallopian Tube Carcinoma × HhAntag691 × Clear all
NCT05538091 2025-11-26

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

University of Pittsburgh

Phase 2 Recruiting
48 enrolled
Gynecologic

Platinum-Resistant Fallopian Tube Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡